Pakistan pharmaceutical market: size, growth and outlook 2026–2032

A large, price-controlled generics market with export ambitions. Published estimates normalised to 2025 range from USD 3.6 bn to USD 3.9 bn; the Consulting Wallah central estimate is USD 4.0 bn, growing at about 9% a year to USD 7.3 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by price deregulation of non-essential medicines in Feb 2024 credited by PPMA for availability and export growth (Profit); retail market value growth of 20-21% in 2024-25, ~69% of it price-driven (IQVIA via Geo); exports up 34% to USD 457 mn in FY25, the fastest growth in two decades (Profit).

Context that matters for buyers and suppliers: Pakistan has 629 pharmaceutical companies and around 800 licensed manufacturing units. Retail pharma market: PKR 1.007 trillion (USD 3.6 bn) in CY2024, 3.73 bn units, volume +2.85%. Six companies (Getz, Sami, Abbott, GSK, Searle, Martin Dow) each exceed PKR 40 bn in sales with a combined 33.7% share (Dec 2024). Record monthly sales PKR 96.48 bn in Oct 2024 (national companies PKR 75.39 bn; MNCs PKR 21.09 bn).

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 3.6 bn–USD 3.9 bn; differences are mostly scope.

Included: prescription and OTC pharmaceuticals, biologics and vaccines across hospital, retail and government channels. Excluded: medical devices, nutrition. Figures at ex-manufacturer vs retail prices differ by 20–40%, which explains part of the published range.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Pakistan has 629 pharmaceutical companies and around 800 licensed manufacturing units (IPRI)
• Retail pharma market: PKR 1.007 trillion (USD 3.6 bn) in CY2024, 3.73 bn units, volume +2.85% (Nukta (IQVIA))
• Six companies (Getz, Sami, Abbott, GSK, Searle, Martin Dow) each exceed PKR 40 bn in sales with a combined 33.7% share (Dec 2024) (Nukta (IQVIA))
• Record monthly sales PKR 96.48 bn in Oct 2024 (national companies PKR 75.39 bn; MNCs PKR 21.09 bn) (Geo News (IQVIA))
• DRAP established 2012 under the DRAP Act; 2018 Drug Pricing Policy; non-essential drugs deregulated Feb 2024 (IPRI; Profit)
• Over 85% of pharmaceutical expenditure is out-of-pocket; ~75% of distribution is private (IPRI citing World Bank 2021)
• Pharma exports FY25 USD 457 mn, over 1% of GDP; import substitution saves ~USD 2 bn/yr (Profit by Pakistan Today)
• Martin Dow Group annual sales exceed USD 200 mn; exports 5% of revenue, targeting 50% within 5-8 years (Profit by Pakistan Today)
• Lucky Core Industries acquired Pfizer Pakistan (IPRI)

Where the GCC and India sit

• Pakistan retail pharma market: PKR 1.007 trillion (USD 3.6 bn) (2024) — IQVIA via Nukta
• Pakistan pharma exports: USD 457 mn (+34%, from USD 341 mn) (FY2025) — Profit by Pakistan Today
• Pakistan therapeutic goods exports (broader): USD 909 mn (FY2025) — Profit by Pakistan Today
• Pakistan pharma imports: PKR 304.1 bn (+7.1%) (FY2024) — IPRI citing SBP
• Afghanistan share of Pakistan pharma exports: ~38% (FY2024) — IPRI citing SBP

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: export target of USD 5 bn/year within eight years; Business Recorder projects USD 1.5 bn by 2030 (Profit); more than USD 500 mn in factory upgrades for international GMP certification (e.g. Martin Dow USD 30 mn) (Profit); mid-term target of 20-30% API localisation (IPRI).

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Manufacturers: registration and a strong local agent decide access; serialisation and GMP inspection readiness shorten the path; localisation stories win public tenders.
• Hospital leaders: class-level lots, biosimilars and IV→oral switch programmes are the three savings levers; the drug repository lists the class members.
• Distributors: buyers increasingly want data (catalogue, serialisation events, fill rates) as much as product.

1. Nukta, Pakistan's retail pharmaceutical market reaches PKR 1.007 trillion in 2024 — nukta.com
2. Geo News, Pakistan's pharma market crosses Rs1tr mark amid price hikes — geo.tv
3. ProPakistani, Pharma sales hit record Rs1.251 trillion yet Pakistanis buy fewer medicines — propakistani.pk
4. Profit by Pakistan Today, Pakistani pharma bets on $500m factory upgrades to break into global markets — profit.pakistantoday.com.pk
5. Profit by Pakistan Today, Pakistan's pharmaceutical exports hit 34% growth in FY25 — profit.pakistantoday.com.pk
6. Islamabad Policy Research Institute (IPRI), Pharmaceutical sector policy paper (Dec 2025) — ipripak.org
7. ProPakistani, Pakistan pharma industry opposes changes to drug pricing policy — propakistani.pk
8. IQVIA via Nukta (2025-02) — PKR 1.007 trillion (USD 3.6 bn), 12 months to Dec 2024; value growth 21.45% (2024) to — (), CAGR —; scope: country - Pakistan retail pharmaceutical market (IQVIA MAT Dec 2024) — source
9. Profit by Pakistan Today (2025-09) — USD 3.29 bn ('last year') (2024) to — (), CAGR —; scope: country - domestic pharmaceutical market — source
10. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
11. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.